Related Experiment Video
Updated: Jan 16, 2026
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Chronic hepatitis E: The neglected liver killer
Chang-Yi Ji1, Meng-Meng Gu2, Lan Huang2
1Anhui Province Key Laboratory of Immunology in Chronic Diseases, Research Center of Laboratory, School of Laboratory, Bengbu Medical University, Bengbu 233000, China.
Background:
Hepatitis E virus (HEV) may induce acute self-limiting illnesses or persistent infections. Chronic hepatitis E frequently occurs in immunocompromised persons, including organ transplant recipients, HIV-positive patients, and those with hematological malignancies. It poses a risk of liver fibrosis and cirrhosis.
Data Sources:
Relevant articles published till September 2024 were located using PubMed searches. The further search terms utilized were: "immunocompromised", "solid organ transplant", "HIV", "hematological malignancy", and "hepatitis E virus". A manual search of references from pivotal articles extended further publications. The search parameters encompass publications in English.
Results:
The epidemiology, clinical manifestations, diagnostic measures, and therapeutic modalities of chronic hepatitis E were discussed. Immunocompromised individuals who are infected with HEV are at an increased risk of developing chronic infections, which may progress to liver fibrosis and cirrhosis. Current understanding of HEV is still limited, and there is no medicine that specifically targets hepatitis E. Consequently, the prevention and management of hepatitis E continue to present a significant challenge.
Conclusions:
Chronic hepatitis E patients need special attention in clinical practice. The relevant risk factors must be identified to facilitate accurate diagnosis and the implementation of more effective preventive measures, thereby enhancing the monitoring, treatment, and prevention of immunocompromised individuals.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...